Tauriga Sciences, Inc. and Breathe eCig Corp. announced that the two companies have entered into a license agreement to co-develop and co-commercialize a new cannabidiol (CBD) e-cigarette. This new product will utilize Breathe's patent pending, proprietary device that dispenses a measured and consistent amount of active ingredient per puff and that also features an optional childproofing device.

Tauriga will be responsible for the active ingredient and will source and qualify the CBD oil and will formulate the contents of the pre-filled cartridges and refill units. Tauriga and Breathe will share the net profits equally from the CBD e-cigarette product line. CBD has been associated with many medicinal properties and therapeutic benefits, yet unlike THC, it does not create a psychoactive ‘high'.

Preclinical studies using animal models suggest that CBD has anticonvulsant, anxiolytic/anti-depressant, anti-inflammatory, antiemetic, and anti-oxidant properties. As such, CBD may have important therapeutic benefits in the treatment of a wide range of conditions, including chronic pain, neurodegenerative diseases, anxiety, nausea, cancer, arthritis, and other health concerns.